Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging randomized trial of dupilumab in adults with moderate-to-severe atopic dermatitis
2012-003651-11Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dupilumab in atopic dermatitis (AD) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change in EASI score from baseline to week 16. Started Apr 2013; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2012-003651-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003651-11.